KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 65 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $224 | -5.5% | 23,250 | -11.6% | 0.01% | +10.0% |
| Q2 2023 | $237 | +5.8% | 26,290 | -7.8% | 0.01% | -9.1% |
| Q1 2023 | $224 | -99.9% | 28,510 | +135.3% | 0.01% | -83.3% |
| Q4 2020 | $230,000 | +28.5% | 12,119 | -14.8% | 0.07% | +15.8% |
| Q3 2020 | $179,000 | +32.6% | 14,219 | +27.8% | 0.06% | +23.9% |
| Q2 2020 | $135,000 | -6.2% | 11,129 | -40.9% | 0.05% | -24.6% |
| Q1 2020 | $144,000 | -42.2% | 18,829 | +34.8% | 0.06% | -17.6% |
| Q4 2019 | $249,000 | -25.2% | 13,969 | -51.4% | 0.07% | -40.3% |
| Q3 2019 | $333,000 | -39.0% | 28,736 | +16.5% | 0.12% | -38.6% |
| Q2 2019 | $546,000 | +14.9% | 24,667 | +48.7% | 0.20% | -25.5% |
| Q1 2019 | $475,000 | +24.3% | 16,591 | -14.2% | 0.27% | +153.3% |
| Q4 2018 | $382,000 | – | 19,341 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |